Blood Res.  2017 Jun;52(2):79-81. 10.5045/br.2017.52.2.79.

Hematopoietic stem cell mobilization: current status and future perspective

• Kim JS

• KMID: 2413321
• DOI: http://doi.org/10.5045/br.2017.52.2.79

Abstract

No abstract available.

MeSH Terms

Hematopoietic Stem Cell Mobilization*
Blood Component Removal
Peripheral Blood Stem Cells
JM 3100

Reference

1. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014; 20:295–308. PMID: 24141007.

2. Kim SJ, Yoon DH, Yang DH, et al. Plerixafor use for peripheral blood stem cell mobilization in Korea. Blood Res. 2013; 48:72–73. PMID: 23826573.

3. Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009; 23:1904–1912. PMID: 19554029.

4. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27:4767–4773. PMID: 19720922.

5. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113:5720–5726. PMID: 19363221.

6. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011; 118:4530–4540. PMID: 21832280.

7. Veltri L, Cumpston A, Shillingburg A, et al. Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy. 2015; 17:1785–1792. PMID: 26475754.

8. Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013; 19:87–93. PMID: 22922211.

9. Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol. 2014; 164:113–123. PMID: 24138497.

10. Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci. 2017; 56:190–198. PMID: 28034547.